Anal Cancer - Pipeline Review, H2 2015

Date: September 9, 2015
Pages: 68
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A0BDFD902DEEN
Leaflet:

Download PDF Leaflet

Anal Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Anal Cancer - Pipeline Review, H2 2015’, provides an overview of the Anal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Anal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Anal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Anal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Anal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Anal Cancer Overview
Therapeutics Development
Pipeline Products for Anal Cancer - Overview
Pipeline Products for Anal Cancer - Comparative Analysis
Anal Cancer - Therapeutics under Development by Companies
Anal Cancer - Therapeutics under Investigation by Universities/Institutes
Anal Cancer - Pipeline Products Glance
Clinical Stage Products
Anal Cancer - Products under Development by Companies
Anal Cancer - Products under Investigation by Universities/Institutes
Anal Cancer - Companies Involved in Therapeutics Development
Advaxis, Inc.
Amgen Inc.
Eli Lilly and Company
ISA Pharmaceuticals B.V.
MedImmune, LLC
Novartis AG
Sun Pharma Advanced Research Company Ltd.
Anal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
axalimogene filolisbac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for HPV Associated Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISA-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel albumin free - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prexasertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anal Cancer - Recent Pipeline Updates
Anal Cancer - Dormant Projects
Anal Cancer - Product Development Milestones
Featured News & Press Releases
Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer
Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer
Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience
Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV
Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV
Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy
Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Anal Cancer, H2 2015
Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Anal Cancer - Pipeline by Advaxis, Inc., H2 2015
Anal Cancer - Pipeline by Amgen Inc., H2 2015
Anal Cancer - Pipeline by Eli Lilly and Company, H2 2015
Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2015
Anal Cancer - Pipeline by MedImmune, LLC, H2 2015
Anal Cancer - Pipeline by Novartis AG, H2 2015
Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Anal Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Anal Cancer - Dormant Projects, H2 2015

LIST OF FIGURES

Number of Products under Development for Anal Cancer, H2 2015
Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Advaxis, Inc.
Amgen Inc.
Eli Lilly and Company
ISA Pharmaceuticals B.V.
MedImmune, LLC
Novartis AG
Sun Pharma Advanced Research Company Ltd.
Skip to top


Anal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 86 pages
Ureter Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 103 pages
Rectal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 112 pages
Thymus Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages

Ask Your Question

Anal Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: